Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 1
1999 3
2000 3
2001 10
2002 30
2003 42
2004 57
2005 89
2006 69
2007 91
2008 62
2009 71
2010 57
2011 42
2012 42
2013 36
2014 18
2015 30
2016 20
2017 24
2018 23
2019 26
2020 19
2021 24
2022 26
2023 20
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

857 results

Results by year

Filters applied: . Clear all
Page 1
Pimecrolimus for psoriasis.
Ayer J, Young HS. Ayer J, et al. Expert Opin Pharmacother. 2013 Apr;14(6):767-74. doi: 10.1517/14656566.2013.775247. Epub 2013 Mar 6. Expert Opin Pharmacother. 2013. PMID: 23461536 Review.
INTRODUCTION: Pimecrolimus is a calcineurin inhibitor which has a role in the treatment of psoriasis. ...EXPERT OPINION: Topical Pimecrolimus is an effective, off-license treatment option particularly for facial and intertriginous psoriasis. ...
INTRODUCTION: Pimecrolimus is a calcineurin inhibitor which has a role in the treatment of psoriasis. ...EXPERT OPINION: Topical P …
Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial.
Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, Schauer U, Qaqundah P, Poulin Y, Kristjansson S, von Berg A, Nieto A, Boguniewicz M, Paller AS, Dakovic R, Ring J, Luger T. Sigurgeirsson B, et al. Pediatrics. 2015 Apr;135(4):597-606. doi: 10.1542/peds.2014-1990. Epub 2015 Mar 23. Pediatrics. 2015. PMID: 25802354 Free article. Clinical Trial.
In this longest and largest intervention study ever conducted in infants with mild-to-moderate AD, pimecrolimus 1% cream (PIM) was compared with TCSs. METHODS: A total of 2418 infants were enrolled in this 5-year open-label study. ...
In this longest and largest intervention study ever conducted in infants with mild-to-moderate AD, pimecrolimus 1% cream (PIM) was co …
Off-label Uses of Topical Pimecrolimus.
Ladda M, Sandhu V, Ighani A, Yeung J. Ladda M, et al. J Cutan Med Surg. 2019 Jul/Aug;23(4):442-448. doi: 10.1177/1203475419847950. Epub 2019 May 3. J Cutan Med Surg. 2019. PMID: 31053034 Review.
This article reviews research that has been published on the off-label uses of topical pimecrolimus, with a focus on published RCTs. Convincing evidence exists supporting pimecrolimus' efficacy in oral lichen planus and seborrheic dermatitis. For other conditions st …
This article reviews research that has been published on the off-label uses of topical pimecrolimus, with a focus on published RCTs. …
Pimecrolimus: a review.
Gupta AK, Chow M. Gupta AK, et al. J Eur Acad Dermatol Venereol. 2003 Sep;17(5):493-503. doi: 10.1046/j.1468-3083.2003.00692.x. J Eur Acad Dermatol Venereol. 2003. PMID: 12941081 Review.
Topical application of pimecrolimus is not associated with skin atrophy. Pimecrolimus is effective and safe in both children and adults with atopic dermatitis. ...Similar results have also been found in children aged 3 months and older following application of pi …
Topical application of pimecrolimus is not associated with skin atrophy. Pimecrolimus is effective and safe in both children a …
Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nuñez JJ, Gomez-Escobar L, Pérez-Herrera LC, Díaz Martinez JP, Brignardello-Petersen R, Sadeghirad B, Wong MM, Ceccacci R, Zhao IX, Basmaji J, MacDonald M, Chu X, Islam N, Gao Y, Izcovich A, Asiniwasis RN, Boguniewicz M, De Benedetto A, Capozza K, Chen L, Ellison K, Frazier WT, Greenhawt M, Huynh J, LeBovidge J, Lio PA, Martin SA, O'Brien M, Ong PY, Silverberg JI, Spergel JM, Smith Begolka W, Wang J, Wheeler KE, Gardner DD, Schneider L. Chu DK, et al. J Allergy Clin Immunol. 2023 Dec;152(6):1493-1519. doi: 10.1016/j.jaci.2023.08.030. Epub 2023 Sep 9. J Allergy Clin Immunol. 2023. PMID: 37678572 Free article.
RESULTS: The 219 included trials (43,123 patients) evaluated 68 interventions. With high-certainty evidence, pimecrolimus improved 6 of 7 outcomes-among the best for 2; high-dose tacrolimus (0.1%) improved 5-among the best for 2; low-dose tacrolimus (0.03%) improved 5-amon …
RESULTS: The 219 included trials (43,123 patients) evaluated 68 interventions. With high-certainty evidence, pimecrolimus improved 6 …
Pimecrolimus in dermatology.
Fabroni C, Lotti T. Fabroni C, et al. G Ital Dermatol Venereol. 2009 Jun;144(3):321-5. G Ital Dermatol Venereol. 2009. PMID: 19528913 Review.
Pimecrolimus is a non-steroidal immunosuppressant derived from ascomycin. This drug inhibits the action of calcineurin phosphatase and blocks the production of inflammatory substances that are thought to be important in causing skin lesions in inflammatory diseases. Pim …
Pimecrolimus is a non-steroidal immunosuppressant derived from ascomycin. This drug inhibits the action of calcineurin phosphatase an …
Topical pimecrolimus for eczema.
Ashcroft DM, Chen LC, Garside R, Stein K, Williams HC. Ashcroft DM, et al. Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD005500. doi: 10.1002/14651858.CD005500.pub2. Cochrane Database Syst Rev. 2007. PMID: 17943859 Free PMC article. Review.
Pimecrolimus was also associated with significantly more overall withdrawals and skin burning. ...The therapeutic role of topical pimecrolimus is uncertain due to the absence of key comparisons with mild corticosteroids....
Pimecrolimus was also associated with significantly more overall withdrawals and skin burning. ...The therapeutic role of topi …
Pediatric mastocytosis.
Hussain SH. Hussain SH. Curr Opin Pediatr. 2020 Aug;32(4):531-538. doi: 10.1097/MOP.0000000000000922. Curr Opin Pediatr. 2020. PMID: 32692050 Review.
Serum tryptase levels may be elevated in pediatric cutaneous mastocytosis patients without systemic mastocytosis. Pimecrolimus, omalizumab and tyrosine kinase inhibitors are effective treatment options. ...
Serum tryptase levels may be elevated in pediatric cutaneous mastocytosis patients without systemic mastocytosis. Pimecrolimus, omali …
Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.
Prucha H, Schnopp C, Akdis C, Lauener R, Wollenberg A, Ring J, Traidl-Hoffmann C. Prucha H, et al. Expert Opin Drug Metab Toxicol. 2013 Nov;9(11):1507-16. doi: 10.1517/17425255.2013.819343. Epub 2013 Jul 22. Expert Opin Drug Metab Toxicol. 2013. PMID: 23876065 Review.
AREAS COVERED: The authors provide a review of pimecrolimus as a treatment for AE. Specifically, the authors present the pharmacokinetic and pharmacodynamic information on pimecrolimus and also review its efficacy. The authors also discuss pimecrolimus' safet …
AREAS COVERED: The authors provide a review of pimecrolimus as a treatment for AE. Specifically, the authors present the pharmacokine …
Pimecrolimus cream for atopic dermatitis.
[No authors listed] [No authors listed] Drug Ther Bull. 2003 May;41(5):33-6. doi: 10.1136/dtb.2003.41533. Drug Ther Bull. 2003. PMID: 12789846 Review.
Pimecrolimus (pronounced pi-me-kro-ly-mus) cream (Elidel--Novartis) is a new topical immunosuppressant licensed for the treatment of patients aged 2 years or over with mild or moderate atopic dermatitis. ...Here, we consider the place of pimecrolimus cream in the ma …
Pimecrolimus (pronounced pi-me-kro-ly-mus) cream (Elidel--Novartis) is a new topical immunosuppressant licensed for the treatment of …
857 results